Sort   by:  
 Page size 
MetabolomicsMethionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
GenomicsSequencing of patient samples who received immune checkpoint inhibition WES NKI
DNA and RNA isolated from FFPE blocks of patients who received immune checkpoint inhibition (ICI) are sequenced with the aim to identify therapeutically tractable vulnerabilities in tumors to prevent ICI resistance.
EGAS00001003154 | EGA
GenomicsImmune Checkpoint Associated Acute Interstitial Nephritis
Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis
EGAD00010002406 | EGA
GenomicsMDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma
MDM2 inhibition enhances immune checkpoint inhibitor therapy in melanoma
PRJNA764915 | ENA
MetabolomicsThe Inhibition of B7H3 by 2-HG Accumulation Is Associated With Downregulation of VEGFA in IDH Mutated Gliomas
B7H3 (also known as CD276) is a co-stimulator checkpoint protein of the cell surface B7 superfamily. Recently, the function beyond immune regulation of B7H3 has been widely studied. However, the expression preference and the regulation mechanism underlying B7H3 in different subtypes of gliomas is ra...
2021-05-26 | MTBLS2692 | MetaboLights
GenomicsA Multifactorial Tumor and Immune Cell Profile Determines Response to Immune Checkpoint blockade in Melanoma
The complex crosstalk between tumor and immune cells during immune checkpoint blockade mandates the development of integrated models that interpret the anti-tumor immune response and predict clinical outcome. We have integrated genome-wide sequence and structural alterations with pre and on-therapy ...
EGAS00001004548 | EGA
GenomicsMutational analysis of an oligoprogressive sarcomatoid hepatocellular carcinoma treated with an immune checkpoint inhibitor.
In this study, we describe a patient diagnosed with metastatic sarcomatoid hepatocellular carcinoma that showed a remarkable tumor response to Nivolumab, an immune checkpoint inhibitor, followed by an oligoprogression. Molecular analysis of the primary tumor in addition to a bone and brain metastasi...
EGAS00001005064 | EGA
GenomicsSingle Cell Transcriptomics of peripheral immune cells pre- and post-Immune Checkpoint Blockade
Raw sequencing data for magnetically-sorted CD8+ T cells and monocytes from the peripheral blood of eight individuals receiving immune checkpoint blockade (either combination ipilimumab/nivolumab, n=4; or single-agent pembrolizumab, n=4) for the treatment of metastatic melanoma. Samples were taken i...
EGAS00001005507 | EGA
TranscriptomicsSingle cell RNA-seq of pancreatic mouse tumors upon treatment
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and resistant to targeted therapies, immune checkpoint blockade and engineered T cells. In this study, we performed a systematic high throughput combinatorial drug screen and identified a synergistic interaction between ...
ORGANISM(S): Mus musculus 
2021-11-13 | E-MTAB-9954 | biostudies-arrayexpress
TranscriptomicsInhibition of PARP14 restores response to α-PD1 immune checkpoint inhibition in tumours with resistance driven by IFNγ. PARP14 study.
While immune checkpoint blockade therapy (ICBT) benefits cancer patients, many fail to maintain their response due to adaptive resistance mechanisms. IFNγ is critical for cellular immunity, but also promotes adaptive resistance to ICBT. We have established a role for PARP14 in mediating IFNγ-induced...
ORGANISM(S): Homo sapiens 
2023-08-08 | E-MTAB-12195 | biostudies-arrayexpress
Sort   by:  
 Page size